Kenechukwu Chiadika Uzoma Moneke
By Elizabeth Osayande
Nigeria’s HIV response stands at a pivotal crossroads. For decades, international partners like USAID and the Global Fund have underwritten critical prevention, testing, and treatment services across the country. But with global funding shrinking and donor fatigue setting in, the long-standing model of externally financed healthcare is under threat. According to the World Health Organisation, setbacks in HIV, tuberculosis, and malaria control are inevitable without continued U.S. support, despite the Nigerian government’s emergency release of $3.2 million in 2023 for HIV medication.
Among the rising voices calling for a strategic pivot is Kenechukwu Chiadika Uzoma Moneke, a digital health researcher and public health expert whose work demonstrates how homegrown innovation can sustain and even accelerate progress in HIV response. His approach fuses grassroots health delivery with AI-powered surveillance and community-driven digital tools, all tailored to the realities of Nigeria’s health system.
Infrastructure Alone Won’t Solve It
For years, HIV programming in Nigeria has depended on vertical investments in laboratories, test kits, ART distribution channels, and foreign-trained consultants. But Moneke and other practitioners now argue that infrastructure alone cannot fill the growing gap. Without intelligent, scalable, and locally embedded systems for surveillance, diagnosis, and follow-up, Nigeria risks reversing the hard-won gains in HIV control.
“Our biggest challenge isn’t just the virus—it’s the fragility of the system that surrounds it,” Moneke explains. “To reach the last mile, we must rethink how data, trust, and care move through our communities.”
Digital Tools, Local Impact
Moneke’s research bridges innovation with frontline implementation. Through his leadership at CHES Empowerment Foundation, he helped coordinate mobile HIV testing units equipped with rapid diagnostics, geospatial data tracking, and vernacular radio messaging—reaching over 5,000 underserved people across urban and rural Southeastern Nigeria.
His recent work—“Strengthening HIV Disease Surveillance in Abuja, Nigeria”—details how digital dashboards and AI-assisted trend analysis can enable early detection of outbreaks and real-time targeting of ART interventions. Another publication, “Enhancing Infectious Disease Management in Nigeria”, outlines the potential for AI to assist in HIV comorbidity diagnostics and improve adherence monitoring through chatbots and mHealth platforms.
More than theory, these interventions have been adopted by local health departments and integrated into state-level reporting frameworks, showing measurable improvement in care continuity and case resolution rates.
Linking Research and Resilience
A firm believer in linking research to policy, Moneke advocates for a National Digital HIV Innovation Strategy—one that embeds AI-powered surveillance, supports local health-tech developers, and institutionalises interoperability between mobile clinics and government health systems.
“Donor funds will fade, but innovation can scale,” he emphasises. “We need to stop outsourcing our survival and start coding our own response mechanisms.”
He also stresses the importance of inclusivity in tech-driven health responses, noting that stigma remains a major barrier to uptake. His models incorporate anonymous reporting, privacy-preserving AI systems, and culturally responsive digital counselling protocols designed for marginalised populations, including young people and rural women.
From Donor Dependence to Data Sovereignty
What Nigeria needs, according to Moneke, is not just more funds, but more resilience—a health architecture that works in real-time, with real data, and is owned by the communities it serves.
“We must move from donor dependency to data sovereignty,” he says. “Let’s stop waiting for foreign tools and start deploying digital systems that are Nigerian-built, Nigerian-run, and future-ready.”
Disclaimer
Comments expressed here do not reflect the opinions of Vanguard newspapers or any employee thereof.